Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)

v3.24.1.u1
Net Loss per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details) - shares
3 Months Ended
Mar. 31, 2024
Apr. 02, 2023
Stock options outstanding    
Subsidiary Sale Of Stock [Line Items]    
Anti-dilutive securities (in shares) 2,514,254 4,608,824
Restricted stock units and performance restricted stock units outstanding    
Subsidiary Sale Of Stock [Line Items]    
Anti-dilutive securities (in shares) 9,726,554 9,821,622
Assumed conversion of Convertible Senior Notes    
Subsidiary Sale Of Stock [Line Items]    
Anti-dilutive securities (in shares) 11,053,800 0
Private Placement Warrants outstanding    
Subsidiary Sale Of Stock [Line Items]    
Anti-dilutive securities (in shares) 6,000,000 6,000,000
Employee stock purchase plan estimated shares    
Subsidiary Sale Of Stock [Line Items]    
Anti-dilutive securities (in shares) 442,146 349,988